Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLP006
MIFTS: 70

Sleep Apnea

Categories: Mental diseases, Neuronal diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Sleep Apnea

About this section

MalaCards integrated aliases for Sleep Apnea:

Name: Sleep Apnea 12 54 29 6 43 15 63
Sleep Apnea Syndromes 44 73

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0050847
ICD10 33 G47.3 G47.30
ICD9CM 35 780.57
MeSH 44 D012891
NCIt 50 C26884
SNOMED-CT 68 73430006
UMLS 73 C0037315
Sources

Summaries for Sleep Apnea

About this section
NINDS : 54 Sleep apnea is a common sleep disorder characterized by brief interruptions of breathing during sleep.  These episodes usually last 10 seconds or more and occur repeatedly throughout the night.  People with sleep apnea will partially awaken as they struggle to breathe, but in the morning they will not be aware of the disturbances in their sleep.  The most common type of sleep apnea is obstructive sleep apnea (OSA), caused by relaxation of soft tissue in the back of the throat that blocks the passage of air.  Central sleep apnea (CSA) is caused by irregularities in the brain’s normal signals to breathe.  Most people with sleep apnea will have a combination of both types.  The hallmark symptom of the disorder is excessive daytime sleepiness. Additional symptoms of sleep apnea include restless sleep, loud snoring (with periods of silence followed by gasps), falling asleep during the day, morning headaches, trouble concentrating, irritability, forgetfulness, mood or behavior changes, anxiety, and depression.  Not everyone who has these symptoms will have sleep apnea, but it is recommended that people who are experiencing even a few of these symptoms visit their doctor for evaluation.  Sleep apnea is more likely to occur in men than women, and in people who are overweight or obese.

MalaCards based summary : Sleep Apnea, also known as sleep apnea syndromes, is related to central sleep apnea and apnea, obstructive sleep, and has symptoms including seizures, tremor and dyspnea. An important gene associated with Sleep Apnea is AHDC1 (AT-Hook DNA Binding Motif Containing 1), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Cafcit Injection and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep.

MedlinePlus : 43 Sleep apnea is a common disorder that causes your breathing to stop or get very shallow. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. The most common type is obstructive sleep apnea. It causes your airway to collapse or become blocked during sleep. Normal breathing starts again with a snort or choking sound. People with sleep apnea often snore loudly. However, not everyone who snores has sleep apnea. You are more at risk for sleep apnea if you are overweight, male, or have a family history or small airways. Children with enlarged tonsils or adenoids may also get it. Doctors diagnose sleep apnea based on medical and family histories, a physical exam, and sleep study results. When your sleep is interrupted throughout the night, you can be drowsy during the day. People with sleep apnea are at higher risk for car crashes, work-related accidents, and other medical problems. If you have it, it is important to get treatment. Lifestyle changes, mouthpieces, surgery, and breathing devices can treat sleep apnea in many people. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 63 About sleep apnea: Sleep apnea (AP-ne-ah) is a common disorder in which you have one or more pauses in breathing or shallow breaths while you sleep.Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. Typically, normal breathing then starts again, sometimes with a loud snort or choking sound.Sleep apnea usually is a chronic (ongoing) condition that disrupts your sleep. When your breathing pauses or becomes shallow, you’ll often move out of deep sleep and into light sleep.As a result, the quality of your sleep is poor, which makes you tired during the day. Sleep apnea is a leading cause of excessive daytime sleepiness.

Wikipedia : 76 Sleep apnea, also spelled sleep apnoea, is a sleep disorder characterized by pauses in breathing or... more...

Sources

Related Diseases for Sleep Apnea

About this section

Diseases in the Sleep Apnea family:

Central Sleep Apnea

Diseases related to Sleep Apnea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 656)
# Related Disease Score Top Affiliating Genes
1 central sleep apnea 34.5 LEP NOS3 NPPB
2 apnea, obstructive sleep 33.3 ADIPOQ CRP EDN1 HCRT HTR2A IL6
3 obesity-hypoventilation syndrome 32.6 ADIPOQ IL6 LEP
4 sleep disorder 32.3 CRP HCRT IL6 INS LEP
5 acromegaly 32.0 GHRL IGF1 INS
6 congestive heart failure 30.8 ACE EDN1 NPPB REN
7 ischemia 30.7 ACE EDN1 ICAM1 NOS3
8 ischemic optic neuropathy 30.7 ACE EDN1 NOS3
9 pulmonary disease, chronic obstructive 30.7 CRP CXCL8 IL6 NPPB TNF
10 post-traumatic stress disorder 30.6 APOE CRP HTR2A
11 nonalcoholic fatty liver disease 30.6 ADIPOQ CRP IL6 INS LEP TNF
12 narcolepsy 30.6 GHRL HCRT LEP TNF
13 coronary artery anomaly 30.6 ACE CRP EDN1 NOS3 NPPB
14 liver disease 30.6 ADIPOQ IL6 INS LEP LEPR TNF
15 nonarteritic anterior ischemic optic neuropathy 30.6 ACE EDN1 NOS3
16 nonalcoholic steatohepatitis 30.5 ADIPOQ INS LEP TNF
17 gestational diabetes 30.5 ADIPOQ INS LEP
18 systolic heart failure 30.5 ACE CRP EDN1 IL6 NPPB
19 pulmonary hypertension 30.4 ACE EDN1 NOS3 NPPB REN
20 respiratory failure 30.4 ACE CRP CXCL8 TNF
21 sexual disorder 30.4 ACE EDN1 NOS3
22 diabetic neuropathy 30.4 ACE INS LEP
23 muscle hypertrophy 30.4 EDN1 IGF1 LEP
24 lung disease 30.3 CXCL8 EDN1 IL6 NPPB TNF
25 tonsillitis 30.3 CXCL8 IL6 TNF
26 retinal vascular disease 30.3 ACE ICAM1 INS
27 fatty liver disease 30.3 ADIPOQ CXCL8 IL6 INS LEP LEPR
28 stroke, ischemic 30.3 ACE APOE CRP NOS3 REN
29 acute myocardial infarction 30.3 ACE CRP EDN1 NPPB
30 carotid stenosis 30.3 ACE APOE CRP TNF
31 asthma 30.2 CXCL8 EDN1 ICAM1 IL6 INS LEP
32 lipid metabolism disorder 30.2 ACE ADIPOQ APOE CRP INS LEP
33 fibromyalgia 30.2 HTR2A IGF1 IL6
34 diabetic macular edema 30.2 ICAM1 IL6 NOS3
35 periodontal disease 30.2 CRP CXCL8 IL6 TNF
36 pneumonia 30.2 CRP CXCL8 IL6 TNF
37 aortic disease 30.1 APOE CRP IL6 REN
38 peripheral vascular disease 30.1 ACE CRP IL6
39 juvenile rheumatoid arthritis 30.1 CRP IL6 TNF
40 complex regional pain syndrome 30.1 EDN1 IL6 TNF
41 interstitial lung disease 30.1 CXCL8 EDN1 IL6 TNF
42 vascular dementia 30.1 ACE APOE TNF
43 peripheral artery disease 30.1 ACE CRP IL6 NOS3
44 ischemic heart disease 30.0 ACE APOE CRP IL6 NOS3 NPPB
45 uremia 30.0 CRP INS LEP
46 arteritic anterior ischemic optic neuropathy 30.0 ACE CRP NOS3
47 otitis media 30.0 CXCL8 IL6 TNF
48 acute mountain sickness 30.0 ACE EDN1 NOS3
49 acute respiratory distress syndrome 30.0 CXCL8 IL6 TNF
50 chronic thromboembolic pulmonary hypertension 30.0 CRP EDN1 NPPB

Comorbidity relations with Sleep Apnea via Phenotypic Disease Network (PDN):


Bronchitis Chronic Pulmonary Heart Disease
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Pulmonary Hypertension, Primary, 1
Respiratory Failure

Graphical network of the top 20 diseases related to Sleep Apnea:



Diseases related to Sleep Apnea
Sources

Symptoms & Phenotypes for Sleep Apnea

About this section

UMLS symptoms related to Sleep Apnea:


seizures, tremor, dyspnea, back pain, apnea, pain, headache, syncope, excessive daytime somnolence, chronic pain, sciatica, wheezing, sleep disturbances, snoring, coughing, cheyne-stokes respiration, vertigo/dizziness, sleeplessness, labored breathing, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Sleep Apnea:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ACE ADIPOQ APOE CRP EDN1 HCRT
2 homeostasis/metabolism MP:0005376 10.43 ACE ADIPOQ APOE CRP EDN1 GHRL
3 behavior/neurological MP:0005386 10.4 ACE ADIPOQ APOE GHRL HCRT HTR2A
4 endocrine/exocrine gland MP:0005379 10.4 ACE ADIPOQ APOE EDN1 GHRL HTR2A
5 growth/size/body region MP:0005378 10.39 ACE ADIPOQ APOE EDN1 HCRT ICAM1
6 adipose tissue MP:0005375 10.33 ACE ADIPOQ APOE GHRL IGF1 IL6
7 immune system MP:0005387 10.32 ACE ADIPOQ APOE CRP ICAM1 IGF1
8 digestive/alimentary MP:0005381 10.31 APOE EDN1 GHRL HTR2A ICAM1 IL6
9 hematopoietic system MP:0005397 10.31 ACE ADIPOQ APOE ICAM1 IGF1 IL6
10 muscle MP:0005369 10.28 ADIPOQ APOE EDN1 HCRT HTR2A ICAM1
11 mortality/aging MP:0010768 10.27 ACE ADIPOQ APOE EDN1 ICAM1 IGF1
12 nervous system MP:0003631 10.18 ADIPOQ APOE EDN1 HCRT ICAM1 IGF1
13 integument MP:0010771 10.15 ADIPOQ APOE ICAM1 IGF1 IL6 INS
14 liver/biliary system MP:0005370 10.13 ACE ADIPOQ APOE IL6 INS LEP
15 renal/urinary system MP:0005367 10.06 ACE ADIPOQ APOE EDN1 IGF1 IL6
16 neoplasm MP:0002006 10.01 ACE ADIPOQ ICAM1 IGF1 IL6 LEP
17 reproductive system MP:0005389 9.96 ACE APOE IGF1 IL6 INS LEP
18 respiratory system MP:0005388 9.81 ADIPOQ APOE HCRT IGF1 IL6 LEP
19 skeleton MP:0005390 9.7 ADIPOQ APOE EDN1 HTR2A IGF1 IL6
20 vision/eye MP:0005391 9.23 APOE ICAM1 IL6 INS LEP LEPR
Sources

Drugs & Therapeutics for Sleep Apnea

About this section

PubMedHealth treatment related to Sleep Apnea: 63

Sleep apnea is treated with lifestyle changes, mouthpieces, breathing devices, and surgery. Medicines typically aren't used to treat the condition.The goals of treating sleep apnea are to:Restore regular breathing during sleepRelieve symptoms such as loud snoring and daytime sleepinessTreatment may improve other medical problems linked to sleep apnea, such as high blood pressure. Treatment also can reduce your risk for heart disease, stroke, and diabetes.If you have sleep apnea, talk with your doctor or sleep specialist about the treatment options that will work best for you.Lifestyle changes and/or mouthpieces may relieve mild sleep apnea. People who have moderate or severe sleep apnea may need breathing devices or surgery.If you continue to have daytime sleepiness despite treatment, your doctor may ask whether you're getting enough sleep. (Adults should get at least 7 to 8 hours of sleep; children and teens need more. For more information, go to the Health Topics Sleep Deprivation and Deficiency article.)If treatment and enough sleep don't relieve your daytime sleepiness, your doctor will consider other treatment options.

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cafcit Injection 18 CAFFEINE CITRATE Roxane Laboratories September 1999

Drugs for Sleep Apnea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4 120014-06-4 3152
2 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Zopiclone Approved Phase 4,Phase 3 43200-80-2 5735
7
Nebivolol Approved, Investigational Phase 4 99200-09-6, 152520-56-4, 118457-14-0 71301
8
Lansoprazole Approved, Investigational Phase 4,Not Applicable 103577-45-3 3883
9
Dexlansoprazole Approved, Investigational Phase 4,Not Applicable 103577-45-3, 138530-94-6 9578005
10
Spironolactone Approved Phase 4,Not Applicable 52-01-7, 1952-01-7 5833
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
13
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 437-38-7 3345
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
17
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
18
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-66-5 1986
19
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
20
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
21
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
22
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
23
Ibuprofen Approved Phase 4,Phase 3,Not Applicable 15687-27-1 3672
24
Adalimumab Approved Phase 4 331731-18-1 16219006
25
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 453 6251
26
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 6740-88-1 3821
27
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
28
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
29
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
30
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112111-43-0
31
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
32
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
33
Remifentanil Approved Phase 4,Early Phase 1,Not Applicable 132875-61-7 60815
34
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
35
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
36
Sodium oxybate Approved Phase 4 502-85-2 5360545
37
Zolpidem Approved Phase 4 82626-48-0 5732
38
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 63006 5281004
39
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
40
Angiotensin II Approved, Investigational Phase 4,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
41
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
42
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
43
Xylometazoline Approved, Investigational Phase 4,Not Applicable 526-36-3 5709
44
Fluticasone Approved, Experimental Phase 4,Phase 3,Not Applicable 90566-53-3 62924
45
Eszopiclone Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 138729-47-2 969472
46
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
47
Valsartan Approved, Investigational Phase 4,Not Applicable 137862-53-4 60846
48
Pantoprazole Approved Phase 4 102625-70-7 4679
49
Eplerenone Approved Phase 4 107724-20-9 443872 150310
50
mometasone furoate Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 83919-23-7

Interventional clinical trials:

(show top 50) (show all 2019)
# Name Status NCT ID Phase Drugs
1 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study Unknown status NCT01796769 Phase 4
2 Donepezil Treatment for Sleep Apnea Patients Unknown status NCT00912457 Phase 4 donepezil;placebo
3 Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01428570 Phase 4
4 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome Unknown status NCT02295202 Phase 4
5 Cardiovascular Impact, Quality e Quantity of Sleep in Bed Partners of Patients With Obstructive Sleep Apnea Unknown status NCT03011294 Phase 4
6 Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study Unknown status NCT01505959 Phase 4
7 Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01590420 Phase 4
8 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. Unknown status NCT02963597 Phase 4
9 Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients Unknown status NCT01524510 Phase 4
10 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
11 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
12 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
13 Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic Unknown status NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
14 Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance Unknown status NCT02820441 Phase 4 Zopiclone;Placebo
15 CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients. Unknown status NCT01771406 Phase 4 Nebivolol
16 Somnodent vs Herbst in Mild and Moderate OSA Patients Unknown status NCT02724865 Phase 4
17 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
18 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
19 Resistant Hypertension Optimal Treatment Unknown status NCT01643434 Phase 4 Spironolactone;Clonidine
20 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
21 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
22 Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing Unknown status NCT00299910 Phase 4 Montelukast
23 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
24 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
25 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
26 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome Completed NCT01635010 Phase 4
27 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
28 Sleep Apnea and Oxidative Stress and Nitric Oxide Completed NCT00547937 Phase 4
29 Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF Completed NCT00551499 Phase 4
30 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy Completed NCT02425202 Phase 4 Ketamine
31 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
32 The Impact of Arousal Threshold in Obstructive Sleep Apnea Completed NCT02264353 Phase 4 Donepezil;placebo
33 Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea Completed NCT01945801 Phase 4 Lasilactone;Placebo
34 CPAP in Diabetes Type 2 Patients With Sleep Apnea Completed NCT01801150 Phase 4
35 Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea Completed NCT02494102 Phase 4 Modafinil;Placebo
36 Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane
37 Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients Completed NCT00741520 Phase 4
38 Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea Completed NCT00307957 Phase 4
39 Serotonin and the Upper Airway in Obstructive Sleep Apnea Completed NCT00100464 Phase 4 Paroxetine;5HTP
40 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
41 Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients Completed NCT00708786 Phase 4
42 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
43 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
44 Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea Completed NCT00772044 Phase 4
45 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
46 Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment Completed NCT00701428 Phase 4 Losartan
47 Nasal Decongestion and Obstructive Sleep Apnea Completed NCT00630474 Phase 4 xylometazoline
48 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
49 Sleep Apnea. Concordance Between Non-reference and Reference Centres Completed NCT00424658 Phase 4
50 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo

Search NIH Clinical Center for Sleep Apnea

Cochrane evidence based reviews: sleep apnea syndromes

Sources

Genetic Tests for Sleep Apnea

About this section

Genetic tests related to Sleep Apnea:

# Genetic test Affiliating Genes
1 Sleep Apnea 29
Sources

Anatomical Context for Sleep Apnea

About this section

MalaCards organs/tissues related to Sleep Apnea:

41
Heart, Testes, Endothelial, Brain, Lung, Tongue, Liver
Sources

Publications for Sleep Apnea

About this section

Articles related to Sleep Apnea:

(show top 50) (show all 4663)
# Title Authors Year
1
Obstructive sleep apnea in non-dialyzed chronic kidney disease patients: Association with body adiposity and sarcopenia. ( 30219685 )
2019
2
Clinical characteristics of obstructive sleep apnea versus infectious adenotonsillar hyperplasia in children. ( 30554693 )
2019
3
Related biomarkers of neurocognitive impairment in children with obstructive sleep apnea. ( 30554705 )
2019
4
Death in patients with adaptive servo-ventilation for sleep apnea and no specific SERVE-HF profile: A case series study. ( 30555779 )
2019
5
Correlates of Endothelial Function in Older Adults With Untreated Obstructive Sleep Apnea and Cardiovascular Disease. ( 30303893 )
2019
6
Obstructive sleep apnea syndrome and olfactory perception: An OERP study. ( 30006255 )
2019
7
PRO: Persistent Central Sleep Apnea/Hunter-Cheyne-Stokes Breathing, Despite Best Guideline-Based Therapy of Heart Failure With Reduced Ejection Fraction, Is a Compensatory Mechanism and Should Not Be Suppressed. ( 29860966 )
2018
8
Transient Central Sleep Apnea Runs Triggered by Disorder of Arousal in a Child. ( 29852907 )
2018
9
Risk of Nephrolithiasis in Patients With Sleep Apnea: A Population-Based Cohort Study. ( 29734978 )
2018
10
Sleep Architecture in Patients With Primary Snoring and Obstructive Sleep Apnea. ( 29967674 )
2018
11
The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome. ( 29973962 )
2018
12
Sleep apnea in Machado-Joseph disease: a clinical and polysomnographic evaluation. ( 29852360 )
2018
13
Alterations of IGF-1, complement C3 and superoxide dismutase in patients with moderate-to-severe obstructive sleep apnea hypopnea syndrome. ( 29441807 )
2018
14
Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity. ( 29649379 )
2018
15
Prevalence, Risk Factors, Outcomes, and Treatment of Obstructive Sleep Apnea in Patients with Cerebrovascular Disease: A Systematic Review. ( 29555400 )
2018
16
Risk of gallstones in patients with obstructive sleep apnea: a nationwide observational cohort study. ( 29980983 )
2018
17
Microstructural cerebral lesions are associated with the severity of central sleep apnea with Cheyne-Stokes-respiration in heart failure and are modified by PAP-therapy. ( 29102807 )
2018
18
Association between obstructive sleep apnea and comorbidities with periodontal disease in adults. ( 29962700 )
2018
19
Forestier syndrome and obstructive sleep apnea: Surgical treatment. ( 29366867 )
2018
20
Axon and Schwann cell degeneration in nerves of upper airway relates to pharyngeal dysfunction in snorers and sleep apnea patients. ( 29966666 )
2018
21
Incidence of Obstructive Sleep Apnea among Patients with Hidradenitis Suppurativa: a retrospective population-based cohort analysis. ( 29957857 )
2018
22
Prevalence and characteristics of positional sleep apnea in the HypnoLaus population-based cohort. ( 29957486 )
2018
23
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
24
Classification methods to detect sleep apnea in adults based on respiratory and oximetry signals: a systematic review. ( 29446755 )
2018
25
Lithuanian dentists' knowledge, attitudes, and clinical practices regarding obstructive sleep apnea: A nationwide cross-sectional study. ( 29431599 )
2018
26
Correlates and Consequences Central Sleep Apnea in a National Sample of U.S. Veterans. ( 29608761 )
2018
27
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
28
Application of 3C insulin pump system in combination with non-invasive ventilation in the treatment of a patient with type 2 diabetes and obstructive sleep apnea syndrome. ( 28429854 )
2018
29
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
2018
30
Evaluation of a Multichannel Non-Contact ECG System and Signal Quality Algorithms for Sleep Apnea Detection and Monitoring. ( 29438344 )
2018
31
Red cell distribution width and uric acid in patients with obstructive sleep apnea. ( 28296212 )
2018
32
Central Sleep Apnea - a Rare Cause for Acute Respiratory Insufficiency in Children. Case Report. ( 29868143 )
2018
33
The effect of positive and negative message framing on short term continuous positive airway pressure compliance in patients with obstructive sleep apnea. ( 29445540 )
2018
34
Certification of fitness to drive in sleep apnea patients: Are we doing the right thing? ( 29962011 )
2018
35
Association between obstructive sleep apnea and alcohol, caffeine and tobacco: a meta-analysis. ( 29971810 )
2018
36
Correlations between pediatric obstructive sleep apnea and longitudinal growth. ( 29447889 )
2018
37
Cycle length identifies obstructive sleep apnea and central sleep apnea in heart failure with reduced ejection fraction. ( 29637409 )
2018
38
Pericardial Effusion in Obstructive Sleep Apnea without Pulmonary Arterial Hypertension and Daily Hypoxemia - is it Unusual? ( 29808980 )
2018
39
MiR-664a-3p expression in patients with obstructive sleep apnea: A potential marker of atherosclerosis. ( 29419680 )
2018
40
Comorbid insomnia and sleep apnea in Veterans with post-traumatic stress disorder. ( 29330769 )
2018
41
Transvenous phrenic nerve stimulation, a novel therapeutic approach for central sleep apnea. ( 29707357 )
2018
42
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. ( 29388045 )
2018
43
Natural history of treatment-emergent central sleep apnea on positive airway pressure: A systematic review. ( 29675059 )
2018
44
Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. ( 29735217 )
2018
45
Pre- and post-operative evaluation of the frequency of nocturnal enuresis and Modified Pediatric Epworth Scale in pediatric obstructive sleep apnea patients. ( 29447815 )
2018
46
Increasing cerebral blood flow reduces the severity of central sleep apnea at high altitude. ( 29389246 )
2018
47
Severe Obstructive Sleep Apnea is Associated with Alterations in the Nasal Microbiome and Increase in Inflammation. ( 29969291 )
2018
48
Correction to: Obstructive sleep apnea does not impair cardiorespiratory responses to progressive exercise performed until exhaustion in hypertensive elderly. ( 29442289 )
2018
49
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
50
Kinesthetic stimulation for obstructive sleep apnea syndrome: An "on-off" proof of concept trial. ( 29449609 )
2018
Sources

Variations for Sleep Apnea

About this section

ClinVar genetic disease variations for Sleep Apnea:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 AHDC1 NM_001029882.3(AHDC1): c.2373_2374delTG (p.Cys791Trpfs) deletion Pathogenic rs587779766 GRCh37 Chromosome 1, 27876253: 27876254
2 AHDC1 NM_001029882.3(AHDC1): c.2373_2374delTG (p.Cys791Trpfs) deletion Pathogenic rs587779766 GRCh38 Chromosome 1, 27549742: 27549743
3 AHDC1 NM_001029882.3(AHDC1): c.2898delC (p.Tyr967Thrfs) deletion Pathogenic rs587779767 GRCh37 Chromosome 1, 27875729: 27875729
4 AHDC1 NM_001029882.3(AHDC1): c.2898delC (p.Tyr967Thrfs) deletion Pathogenic rs587779767 GRCh38 Chromosome 1, 27549218: 27549218
5 AHDC1 NM_001029882.3(AHDC1): c.2547delC (p.Ser850Profs) deletion Pathogenic rs587779768 GRCh37 Chromosome 1, 27876080: 27876080
6 AHDC1 NM_001029882.3(AHDC1): c.2547delC (p.Ser850Profs) deletion Pathogenic rs587779768 GRCh38 Chromosome 1, 27549569: 27549569
7 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh37 Chromosome MT, 9355: 9355
8 MT-CO3 NC_012920.1: m.9355A> T single nucleotide variant Uncertain significance GRCh38 Chromosome MT, 9355: 9355
Sources

Expression for Sleep Apnea

About this section
Search GEO for disease gene expression data for Sleep Apnea.
Sources

Pathways for Sleep Apnea

About this section

Pathways related to Sleep Apnea according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.16 APOE CXCL8 EDN1 GHRL HCRT HTR2A
2
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.54 ADIPOQ APOE CXCL8 IL6 INS LEP
3
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.75 ADIPOQ IL6 INS LEP TNF
4
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.39 ADIPOQ IGF1 INS LEP LEPR
6
Selenium Micronutrient Network 1
Show member pathways
 12.24 APOE CRP ICAM1 IL6 INS TNF
7
IL-1 Family Signaling Pathways 65
Show member pathways
 12.2 CXCL8 EDN1 IL6 TNF
8
Dilated cardiomyopathy (DCM) 37
Show member pathways
 12.19 ACE IGF1 IL6 TNF
9
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.14 CXCL8 HTR2A IL6 TNF
10
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.13 EDN1 IGF1 NPPB TNF
11
Peptide hormone metabolism 66
Show member pathways
 12.11 ACE GHRL IGF1 INS LEP REN
12
Fluid shear stress and atherosclerosis 37
12.06 EDN1 ICAM1 NOS3 TNF
13
Interleukin-4 and 13 signaling 66
11.96 CXCL8 ICAM1 IL6 TNF
14
Spinal Cord Injury 1
11.95 CXCL8 ICAM1 IL6 LEP TNF
15
TNF signaling pathway 37
11.93 EDN1 ICAM1 IL6 TNF
16
Insulin resistance 37
Show member pathways
 11.92 IL6 INS NOS3 TNF
17
Senescence and Autophagy in Cancer 1
11.89 CXCL8 IGF1 IL6 INS
18
HIF-1 signaling pathway 37
11.85 EDN1 IGF1 IL6 INS NOS3
19
Rheumatoid arthritis 37
11.81 CXCL8 ICAM1 IL6 TNF
20
Glucocorticoid receptor regulatory network 1
11.77 CXCL8 ICAM1 IL6
21
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 61
Show member pathways
 11.76 ACE NOS3 REN
22
Pertussis 37
11.73 CXCL8 IL6 TNF
23
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.7 IGF1 IL6 TNF
24
Adipocytokine signaling pathway 37
11.69 ADIPOQ LEP LEPR TNF
25
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 CXCL8 ICAM1 IL6 TNF
26
ATF-2 transcription factor network 1
11.58 CXCL8 IL6 INS
27
Legionellosis 37
11.57 CXCL8 IL6 TNF
28
Adipogenesis 1
11.55 ADIPOQ IGF1 IL6 INS LEP TNF
29
Signaling events mediated by PTP1B 1
11.52 INS LEP LEPR
30
Interleukin-10 signaling 66
11.52 CXCL8 ICAM1 IL6 TNF
31
Malaria 37
11.5 CXCL8 ICAM1 IL6 TNF
32
amb2 Integrin signaling 1
11.49 ICAM1 IL6 TNF
33
Differentiation Pathway 1
11.49 IGF1 IL6 INS
34
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.45 APOE IGF1 IL6 TNF
35
Lung fibrosis 1
11.35 CXCL8 EDN1 IGF1 IL6 TNF
36
African trypanosomiasis 37
11.33 ICAM1 IL6 TNF
37
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.31 CXCL8 IL6 NOS3
38
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.18 CRP EDN1 LEP LEPR
39
AGE-RAGE signaling pathway in diabetic complications 37
11.1 CXCL8 EDN1 ICAM1 IL6 NOS3 TNF
40
Transcription factor regulation in adipogenesis 1
10.97 ADIPOQ IL6 LEP TNF
41
Overview of nanoparticle effects 1
10.84 CRP CXCL8 IL6 TNF
Sources

GO Terms for Sleep Apnea

About this section

Cellular components related to Sleep Apnea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 ACE ADIPOQ APOE CRP CXCL8 EDN1
2 extracellular space GO:0005615 9.5 ACE ADIPOQ APOE CRP CXCL8 EDN1

Biological processes related to Sleep Apnea according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.97 ADIPOQ EDN1 ICAM1 LEP
2 response to lipopolysaccharide GO:0032496 9.96 EDN1 ICAM1 NOS3 REN
3 cellular response to lipopolysaccharide GO:0071222 9.96 CXCL8 ICAM1 IL6 TNF
4 negative regulation of gene expression GO:0010629 9.96 ACE APOE EDN1 IGF1 TNF
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.94 EDN1 GHRL HCRT HTR2A
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 ICAM1 IL6 INS TNF
7 cholesterol metabolic process GO:0008203 9.91 APOE LEP LEPR
8 cellular response to interleukin-1 GO:0071347 9.91 CXCL8 EDN1 ICAM1
9 positive regulation of MAPK cascade GO:0043410 9.91 IGF1 IL6 INS LEP
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IGF1 IL6 LEP
11 response to glucocorticoid GO:0051384 9.88 ADIPOQ IL6 TNF
12 cellular response to drug GO:0035690 9.88 ADIPOQ EDN1 REN
13 positive regulation of MAP kinase activity GO:0043406 9.87 EDN1 HTR2A